Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Latest Features
LATEST ARTICLES
Books, Movies, and Journaling Aid Coping During, After Cancer Treatment
An exploration of complementary therapies that help patients cope during and after treatment for cancer.
Eponyms in Oncology: Zollinger-Ellison Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Zollinger-Ellison syndrome.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Ovarian Cancer Is Not a Silent Killer
Barbara Goff, MD, discusses ovarian cancer and how recognizing symptoms can lead to early detection and reduce misdiagnosis.
Eponyms in Oncology: Li-Fraumeni Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
Moderna’s COVID-19 Vaccine May Be More Effective for Cancer Patients
Growing evidence suggests that patients with cancer have better responses to the Moderna COVID-19 vaccine than to the Pfizer-BioNTech vaccine.
Use of Medical Crowdfunding in Young Adult Cancer Survivors
Researchers investigated how young adult cancer survivors felt about using medical crowdfunding to help cover their healthcare and basic living costs.
USPSTF No Longer Recommends Aspirin as Prophylaxis for Colorectal Cancer
The new guidelines say there is insufficient evidence to support using aspirin to reduce colorectal cancer incidence or mortality.
Eponyms in Oncology: Lynch Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Lynch syndrome.
Gender Pay Gap Affects Most Medical Specialties, Persists Over Time
Women in academic medicine typically have lower starting salaries than men, and this disparity remains after 10 years on the job.
Most Blood Cancer Drug Trials Are Not Randomized, Use Surrogate Endpoints
Of more than 2500 trials analyzed, 21% were randomized.
Eponyms in Oncology: HeLa Cells
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
Eponyms in Oncology: Waldenström Macroglobulinemia
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Findings Support Retesting for MMRD at Uterine Cancer Recurrence
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...